Maxpro Capital Acquisition (JMAC) Competitors $0.15 -0.01 (-6.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends JMAC vs. COEP, ATHE, OBSV, GLTO, BIOR, SYRS, CANF, ABVC, BCLI, and GTBPShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Coeptis Therapeutics (COEP), Alterity Therapeutics (ATHE), ObsEva (OBSV), Galecto (GLTO), Biora Therapeutics (BIOR), Syros Pharmaceuticals (SYRS), Can-Fite BioPharma (CANF), ABVC BioPharma (ABVC), Brainstorm Cell Therapeutics (BCLI), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Coeptis Therapeutics Alterity Therapeutics ObsEva Galecto Biora Therapeutics Syros Pharmaceuticals Can-Fite BioPharma ABVC BioPharma Brainstorm Cell Therapeutics GT Biopharma Maxpro Capital Acquisition (NASDAQ:JMAC) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap unclassified companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Which has more risk & volatility, JMAC or COEP? Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Does the MarketBeat Community believe in JMAC or COEP? Coeptis Therapeutics received 5 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMaxpro Capital AcquisitionN/AN/ACoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Does the media prefer JMAC or COEP? In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score. Company Overall Sentiment Maxpro Capital Acquisition Neutral Coeptis Therapeutics Neutral Do institutionals and insiders believe in JMAC or COEP? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend JMAC or COEP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, JMAC or COEP? Maxpro Capital Acquisition has higher earnings, but lower revenue than Coeptis Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/ACoeptis Therapeutics$80K99.66-$21.27M-$0.29-0.67 Is JMAC or COEP more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Coeptis Therapeutics N/A -1,094.50%-219.97% SummaryMaxpro Capital Acquisition and Coeptis Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$2.01M$257.55M$111.62M$8.82BDividend YieldN/A7.63%5.21%4.07%P/E RatioN/A9.088.6517.81Price / SalesN/A119.820.9774.57Price / CashN/A84.56103.1432.53Price / BookN/A91.26519.864.68Net IncomeN/A$32.24M$2.82M$226.08M7 Day Performance37.43%-0.21%-0.19%-1.04%1 Month Performance9.50%-4.81%-3.22%1.04%1 Year Performance-81.28%14.31%15.40%26.28% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$0.15-6.3%N/A-98.5%$2.01MN/A0.002,021Gap DownHigh Trading VolumeCOEPCoeptis TherapeuticsN/A$0.19+0.1%N/A-83.3%$7.97M$80,000.000.002ATHEAlterity Therapeutics3.1358 of 5 stars$1.09+3.8%$4.00+267.0%N/A$7.96MN/A0.0010OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150GLTOGalecto3.1146 of 5 stars$5.84+0.5%$10.00+71.2%-60.6%$7.71MN/A0.0040Gap UpBIORBiora Therapeutics2.5866 of 5 stars$1.62flat$23.00+1,319.8%-87.9%$7.32MN/A0.00120Analyst ForecastSYRSSyros Pharmaceuticals4.0805 of 5 stars$0.27-6.2%$3.33+1,125.9%-89.9%$7.30M$9.94M-0.10120Analyst RevisionCANFCan-Fite BioPharma1.8668 of 5 stars$2.02+0.5%$18.00+791.1%-1.7%$7.15M$740,000.000.008Analyst DowngradeNews CoverageABVCABVC BioPharma0.751 of 5 stars$0.55-3.1%N/A-66.4%$7.14M$150,000.00-0.6630Gap UpBCLIBrainstorm Cell Therapeutics4.4474 of 5 stars$1.23-2.4%$30.00+2,339.0%-53.4%$7.01MN/A0.0040Analyst UpgradePositive NewsGTBPGT Biopharma0.0716 of 5 stars$3.09-3.1%N/A-54.2%$6.89MN/A0.008 Related Companies and Tools Related Companies COEP Competitors ATHE Competitors OBSV Competitors GLTO Competitors BIOR Competitors SYRS Competitors CANF Competitors ABVC Competitors BCLI Competitors GTBP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JMAC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JMAC Stock Alerts